Literature DB >> 9379129

Selective modification of insulin action in adipose tissue by hyperthyroidism.

L G Fryer1, M J Holness, M C Sugden.   

Abstract

Adipose-tissue lipolysis (assessed from glycerol release) and glucose uptake were examined in parametrial and mesenteric adipocytes prepared from control or hyperthyroid rats in relation to changes in insulin sensitivity. Basal rates of lipolysis did not differ significantly between adipose-tissue depots. Lipolysis was maximally stimulated by noradrenaline at 1 microM, half-maximal anti-lipolytic effects of insulin were observed at approximately 11 microU/ ml insulin, and half-maximal stimulation of glucose uptake was observed at approximately 16 microU/ml insulin in adipocytes from both depots. Wortmannin caused a dose-dependent inhibition of the anti-lipolytic effect of insulin (150 microU/ml) on noradrenaline-stimulated lipolysis. Half-maximal effects of wortmannin were observed at 20-40 nM. The p70S6K inhibitor rapamycin and the mitogen-activated protein kinase kinase inhibitor PD098059 had no effects on noradrenaline-stimulated lipolysis. Hyperthyroidism increased basal rates of lipolysis and the maximal response of lipolysis to noradrenaline stimulation (3.1-fold, P < 0.001 and 2.1-fold, P < 0.05 respectively) in parametrial adipocytes. Hyperthyroidism markedly blunted the sensitivity of noradrenaline-stimulated lipolysis to half-maximal suppression by insulin in both parametrial and mesenteric adipocyte depots, and noradrenaline-stimulated lipolysis at a maximal insulin concentration remained significantly higher in adipocytes prepared from hyperthyroid rats compared with controls. Hyperthyroidism had no effect on basal and little effect on insulin-stimulated glucose uptake. Tri-iodothyronine administered at a low dose selectively influenced the anti-lipolytic action of insulin in parametrial adipocytes, and led to significantly less marked elevation in plasma non-esterified fatty acid concentrations in vivo. The results demonstrate a selective effect of hyperthyroidism to impair insulin's anti-lipolytic action, and are consistent with the operation of different downstream signalling mechanisms for the effects of insulin on adipocyte glucose transport and lipolysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9379129     DOI: 10.1677/joe.0.1540513

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

1.  Hyperthyroidism impairs pancreatic beta cell adaptations to late pregnancy and maternal liporegulation in the rat.

Authors:  M J Holness; G K Greenwood; N D Smith; M C Sugden
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

2.  Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone.

Authors:  Mark J Holness; Karen Bulmer; Nicholas D Smith; Mary C Sugden
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

3.  Evaluation of the role of peroxisome-proliferator-activated receptor alpha in the regulation of cardiac pyruvate dehydrogenase kinase 4 protein expression in response to starvation, high-fat feeding and hyperthyroidism.

Authors:  Mark J Holness; Nicholas D Smith; Karen Bulmer; Teresa Hopkins; Geoffrey F Gibbons; Mary C Sugden
Journal:  Biochem J       Date:  2002-06-15       Impact factor: 3.857

4.  Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects.

Authors:  Haiying Yu; Yan Yang; Muxun Zhang; Huiling Lu; Jianhua Zhang; Hongwei Wang; Katherine Cianflone
Journal:  Nutr Metab (Lond)       Date:  2006-02-10       Impact factor: 4.169

5.  The causal role of breakfast in energy balance and health: a randomized controlled trial in lean adults.

Authors:  James A Betts; Judith D Richardson; Enhad A Chowdhury; Geoffrey D Holman; Kostas Tsintzas; Dylan Thompson
Journal:  Am J Clin Nutr       Date:  2014-06-04       Impact factor: 7.045

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.